Berenberg Bank Cuts AstraZeneca (LON:AZN) Price Target to £150

AstraZeneca (LON:AZN) had its price objective reduced by Berenberg Bank from £160 to £150 in a research note issued to investors on Tuesday, Marketbeat Ratings reports. They currently have a buy rating on the biopharmaceutical company’s stock.

AZN has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating and set a £115 price target on shares of AstraZeneca in a research report on Wednesday, September 2nd. Jefferies Financial Group reissued a “buy” rating and issued a £175 price objective on shares of AstraZeneca in a report on Wednesday, September 9th. Royal Bank Of Canada reissued an “outperform” rating and issued a £145 target price on shares of AstraZeneca in a research note on Tuesday, September 8th. Finally, Citigroup raised their target price on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of £150.

AstraZeneca Stock Performance

AZN opened at £124.28 on Tuesday. AstraZeneca has a 52-week low of £107.84 and a 52-week high of £157.32. The firm has a market capitalization of £192.75 billion, a PE ratio of 18.60, a PEG ratio of 0.86 and a beta of 0.20. The company has a debt-to-equity ratio of 64.10, a quick ratio of 0.59 and a current ratio of 0.89. The business’s 50-day simple moving average is £121.79 and its 200 day simple moving average is £134.47.

Insider Transactions at AstraZeneca

In other news, insider Michel Demare bought 2,500 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was acquired at an average cost of £121.21 per share, for a total transaction of £303,025. Company insiders own 0.15% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.